中期経営計画の修正に関するお知らせ （平成29年12月期～平 …

1 29 12 31 12 . 29 .. 29 -1303 -1129 .. 29 13 .. -1303 -1129 .. -1303 -1129 .. 28 12 29 . 12 30 12 31 12 .. Phase Phase a Phase b Phase . -1129 -1303 .. Phase Phase a Phase b Phase . -1129 -1303 .. 29 12 31 12 . 29 .. 1 .. 26 12 . -115 . -1129 -1303 . 168 . -1337 . 226 255 . 482 . 319 290 304 295. 253 296 .. 3 . 1 3 -1337 28 .. 27 11 JIT .. 2 .. JIT .. -1- . -1129 -1303 . -1337 . -134 .. JIT .. -1002 BBG250 JIT . 29 . -1002 BBG250 . 29 4 30 .. 3 . 1 . 26 12 28 12 .. 26 .. -1129 -1303 . 28 . 29 12 31 12 .. -134 .. -1337 28 . Allysta Pharmaceuticals, Inc. Allysta 30 .. -1129 . 29 -1129 .. 2 .. JIT .. -2- .. -1002 Dutch Ophthalmic Research Center International DORC ILM-Blue MEMBRANEBLUE-DUAL.

2 30 12 . 31 12 . -1108 .. 31 12 6 .. 3 . 7 .. 1 .. 28 12 168 319 304 253. 29 12 380 680 720 1,670. 330 870 880 870. 30 12 . 940 140 150 150. 690 100 100 60. 31 12 . 890 300 300 230. 1 . 2 .. 29 31 26 12 .. 30 31 . 29 31 -1129 -1303 .. -1129 .. 30 .. 29 31 -1002 . 29 . 29 4 30 .. -3- .. 29 31 JIT .. JIT .. 29 30 -1337 .. 29 31 -1002 .. 29 30 -1337 -1002 .. 28 12 226 -1337 . 29 12 760 -1002 . 30 12 790 910 . 31 12 280 .. 29 31 28 12 .. JIT 29 30.. 28 12 2,645 .. 29 16 29 22 . 600 . 31 12 .. 27 7 . 29 . 1,994 .. -4- . 1 . Phase Phase a Phase b Phase . -115.. -1129 -1303 .. -1337.. -134.. -1002.. -1002.. -1002 -1108 .. 31 12 . -1002.. 28 12 . -1129 -1337 -1002 29 12.

3 30 12 31 12 .. -1002 -1108 . 29 12 30 12 . 31 12 .. -5- .. -134 .. -1337 Allysta . -1129 .. -1002 .. 2 .. / -115 -134. 10 . Rho 11 .. 12 . - .. 13 .. Phase b . Phase Phase a .. -6- .. -1129 -1303 -1337.. Allysta .. Phase .. -7- . -1002. BBG250 Brilliant Blue G-250 . NSAIDs 14 . NSAIDs .. DORC .. DORC .. DORC .. 15 .. TOBIRA .. -8- .. TOBIRA .. TOBIRA.. JIT .. -9- 3 . 29 12 -1129. -1303 -1002 . -1129 JIT .. 30 12 ) -1002 . -1129 . JIT . 31 12 ( ) -1129 . -1002 . JIT .. 560 1,190 .. 29 30 . -1337 -1002 .. -1129 -1303 -134 . -1002 . -134 -1129 -1303 . -1002 -1108 -1002 DORC .. JIT .. -10- 4 .. - .. 14 11 .. -1129 -1303 .. 25 29 .. 10 . -134. - .. 14 11.

4 ( ) .. -11- . 13 22 .. -1337. Master Service Agreement Allysta Pharmaceuticals, Inc. 28 18 . Allysta Pharmaceuticals, Inc. -1337 .. EU .. Allysta Pharmaceuticals, Inc.. -1129.. 29 . -1129 .. -1129 .. 60 -1129 .. -1129 .. (1) .. (2) .. (3) .. (4) . 10 . 10% .. -1002.. 29 31 .. -12- . 10 .. BBG250 .. 29 28 . 29 30 .. BBG250 .. 29 30 . -1108 .. 26 12 .. BBG250 .. LICENSE AGREEMENT FOR DYME. Dutch Ophthalmic Research Center International 21 . 21 37 12 . BBG250 .. 21 12 25 . 22 29 12 31 .. -13- .. 27 11 13 . 27 11 13 .. 60 40 .. 29 16 . 600 . 29 22 . 35 12 31 .. (1) .. (2) 10 .. (3) . 1.. 2.. 3.. 4.. (4) .. (5) .. (1) .. -14- (2) .. (3) 2019. 6 .. (4) 10.

5 -15- .. 2005 .. 10 .. 140 .. Rho . 16 Rho-ROCK .. -16- 10 .. 11 .. 12 .. 13 . 1 . 14 NSAIDs Non-Steroidal Anti-Inflammatory Drugs .. 15 .. 16 .. -17.